Erschienen in:
01.07.2014 | Original Article
A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors
verfasst von:
Jennifer S. Gewandter, Supriya G. Mohile, Charles E. Heckler, Julie L. Ryan, Jeffrey J. Kirshner, Patrick J. Flynn, Judith O. Hopkins, Gary R. Morrow
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 7/2014
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Chemotherapy-induced peripheral neuropathy (CIPN) occurs in as high as 70 % of patients receiving certain types of chemotherapy agents. The FDA has yet to approve a therapy for CIPN. The aim of this multicenter, phase III, randomized, double-blind, placebo-controlled trial was to investigate the efficacy of 2 % ketamine plus 4 % amitriptyline (KA) cream for reducing CIPN.
Methods
Cancer survivors who completed chemotherapy at least 1 month prior and had CIPN (>4 out of 10) were enrolled (N = 462). CIPN was assessed using average scores from a 7-day daily diary that asks patients to rate the average “pain, numbness, or tingling in [their] hands and feet over the past 24 h” on an 11-point numeric rating scale at baseline and 6 weeks post intervention. ANCOVA was used to measure differences in 6-week CIPN with effects including baseline CIPN, KA treatment arm, and previous taxane therapy (Y/N).
Results
The KA treatment showed no effect on 6-week CIPN scores (adjusted mean difference = −0.17, p = 0.363).
Conclusions
This study suggests that KA cream does not decrease CIPN symptoms in cancer survivors.